| breast cancer - HR positive | ||
| la/mBC - HR positive | la/mBC - HR positive - L2 - all population | |
| chemotherapy | ||
| non platinum-based chemotherapy | ||
| microtubul inhibitor | ||
| eribulin | NCT03051659 | |
| pegylated liposomal doxorubicin and cyclophosphamide | ICON | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-